For example, many pathogenic cytokines proceed through JAK/STAT signaling such as IL‐13, IL‐23, and IFN‐γ; therefore, JAK inhibitors (e.g., Tofacitinib) are clinically used in IBD treatment.251. This evidence concerns the gene IFNG and inflammatory bowel disease.